Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Francesco Cognetti et al.|The Lancet Oncology|2018Cited by 88
Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in <i><scp>KRAS</scp></i> wild‐type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesco Di Costanzo, Francesca Di Fabio et al.|Cancer Medicine|2016Cited by 26
PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)Bruno Daniele, Maria Carmela Piccirillo, R. V. Iaffaioli et al.|Annals of Oncology|2016Cited by 1
Italian observational study in patients with metastatic colorectal cancer (mCRC) treated with first-line cetuximab based regimen (ObservEr study).Francesca Di Fabio, Carmine Pinto, Gerardo Rosati et al.|Journal of Clinical Oncology|2014Cited by 1
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER TrialMaria Carmela Piccirillo, Bruno Daniele, Antonio Avallone et al.|Clinical Colorectal Cancer|2020Cited by 0